Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × Calcium Dobesilate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 39 Recurrence 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Neoplasms, Plasma Cell 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma 3 Leukemia 3 Myelodysplastic Syndromes 2 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Immunoglobulin Light-chain Amyloidosis 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Amyloidosis 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Smoldering Multiple Myeloma 1 Rectal Neoplasms 1 Proteostasis Deficiencies 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphodepleting Chemotherapy 1 Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 66 Nivolumab 50 Ipilimumab 38 Cyclophosphamide 29 aldesleukin 23 Interleukin-2 22 Temozolomide 17 fludarabine 15 Biopsy 11 trametinib 9 fludarabine phosphate 9 dabrafenib 9 Dacarbazine 8 sargramostim 7 Paclitaxel 7 Cisplatin 7 Bevacizumab 7 lenvatinib 6 cemiplimab 6 binimetinib 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 epacadostat 5 Vemurafenib 5 Specimen Handling 5 Radiotherapy 5 Magnetic Resonance Spectroscopy 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 toripalimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡